All Biosimilars Interchangeable? FDA Backs Switching With Spotlight On Science
Latest Review From US Agency Finds ‘Zero Difference’ In Risks When Switching
The FDA found biosimilar switching produced ‘zero difference’ in key risks • Source: Shutterstock 
